BJB24 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
BJB24 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed BJB24 in detail.
, Design, Synthesis, and Biological Evaluation of Ultrashort β‐Peptoids as Inhibitors of SARS‐CoV‐2 3CL Protease, ChemistrySelect, doi:10.1002/slct.202504383
AbstractThe severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), causative agent of coronavirus disease 2019 (COVID 19), remains a global health burden. The relative success of Paxlovid as the only FDA approved oral pill for COVID19 validates Mpro as a viable antiviral target. Similarly, the limitations of nirmatrelvir, the active ingredient in Paxlovid with its peptide character, present an opportunity for further development of a new generation of oral therapeutics against SARS‐CoV‐2. In the current study, a novel class of ultrashort β‐peptoid nirmatrelvir‐mimetics, equipped with nitrile or alkyne warheads, were designed, synthesized, and screened for antiviral activity against SARS‐CoV‐2 Mpro. Out of thirty (30) ultrashort α‐ and β‐peptoids studied, compound BJB24, a novel β‐peptoid designed to mimic nirmatrelvir, was the most potent, with 98.36% inhibition at 200 µM and IC50 of 7.9 µM. Based on the in vitro activity, very good calculated pharmacokinetic profile, and its distinct advantages as a β‐peptoid, BJB24 and similar ultrashort β‐peptoids warrant further investigation as a new class of antiviral agents.